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1. Introduction
1.1. The nuclear envelope
The nucleus is the defining characteristic organelle of the eukaryotes, and contains the nu‐
clear genome. It is segregated from the cellular cytoplasm by the bilayer nuclear envelope
(Figure 1), which consists of concentric inner and outer nuclear membranes, between which
lies the perinuclear space. The outer nuclear membrane is contiguous with the rough endo‐
plasmic reticulum, like which it is studded with protein producing ribosomes, and the peri‐
nuclear space is contiguous with the lumen of the endoplasmic reticulum. Transport across
the nuclear envelope is accommodated by nuclear pore complexes (NPCs). The NPCs are
the site where the inner and outer nuclear membranes are connected, as their shared lipid
bilayers are united at that point. These NPCs are large, complex and heterogeneous protein
structures, made up of multiple copies of approximately 30 different proteins, called nucleo‐
porins [1]. NPCs span the inner and outer nuclear membranes, and allow the regulated relo‐
cation of molecules between the nucleoplasm and cytoplasm. While smaller molecules, such
as small metabolites or proteins under 40 kDa, are passively transported through the NPCs,
larger molecules such as mRNAs, tRNAs, ribosomes and signalling molecules can be active‐
ly transported from the nucleus, while signalling molecules, proteins, lipids and carbohy‐
drates are actively transported both into and out of the nucleus [2,3].
The inner nuclear membrane is embedded by various inner nuclear membrane proteins,
such as LAP1, LAP2 and MAN1, which are involved in cell cycle control, linking the nucleus
to the cytoskeleton and chromatin organisation [4,5]. Underlying and connected by various
nuclear envelope proteins to the inner nuclear membrane are the nuclear lamina, a thin
(30-100nm) and densely woven fibrillar mesh of intermediate filaments, composed of evolu‐
tionarily conserved lamins A, B1, B2 and C, and lamin associated proteins. These proteins
are closely associated with the NPCs (Figure 1). This assembly of outer nuclear membrane,
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inner nuclear membrane, NPCs, and the lamina can be thought of as complex interface, cou‐
pling the nuclear genome to the rest of the cell, allowing for a sophisticated means of regu‐
lated traffic between inner and outer nuclear space, while compartmentalising DNA
replication, RNA transcription and mRNA editing from translation at the ribosomes [3].
Figure 1. Structure of the nuclear envelope and associated proteins. The nuclear A-type and B-type lamins under‐
lay the nucleoplasmic side of the inner nuclear membrane, and provide stability to the nucleus, an organisational
binding platform for chromatin, and facilitate localisation and binding of nuclear pore complexes as well as a large
family of nuclear envelope proteins. ONM, outer nuclear membrane; PNS, perinuclear space; INM, Inner nuclear mem‐
brane; NE, Nuclear envelope; NPC, Nuclear pore complex; ER, Endoplasmic reticulum, The structures on the ER repre‐
sent ribosomes.
The nuclear lamins are type V intermediate filaments (IFs), and are closely related to the cy‐
toplasmic intermediate filaments (types I-IV, which include the keratins), differing by the
presence of a nuclear localisation signal (NLS) located in the initial section of the tail domain
[6]. Physically, these lamins have the characteristic tripartite assemblage of intermediate fila‐
ments; a short globular N-terminal head domain and a long C-terminal tail domain contain‐
ing an immunoglobin-like domain, separated by a conserved central alpha-helical rod
domain (Figure 4). Coiled-coil homodimers of A- and B-type lamins are formed by interac‐
tion between adjacent heptad hydrophobic repeats on the central rod domain, and charged
residues along the centre of this dimer promote further assembly between dimers, leading to
assembly of filamentous fibrils, whereas the N and C terminal endings facilitate head-to-tail
polymerisation [6-8]. The nuclear lamina has been shown to have a major role in nuclear
structure, heterochromatin organisation and gene regulation [8-11].
1.2. The lamins
The LMNA gene (Online inheritance in man: 150330) is located on chromosome 1q21.2-q21.3
and is composed of 12 exons. Exon 1 codes the N-terminal head domain, exons 1-6 code the
central rod domain, and exons 7-9 code the C-terminal tail domains. Exon 7 also contains the
6 amino acid NLS, necessary for importation of the protein into the nucleus by nuclear
transport through NPCs [6,12,13]. Exons 11 and 12 specifically code lamin A, and the CaaX
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motif of prelamin A (the immature form of lamin A) is located in exon 12. The CaaX motif is
a series of four amino acids at the C-terminus of a protein, consisting of a cysteine, two of
any aliphatic amino acid, and a terminal amino acid. It is important for the post-translation‐
al processing including farnesylation. The motif is identified by the prenyltransferases, far‐
nesyltransferase, or geranylgeranyltransferase-I, and is modified and removed during
maturation of lamin A [14]. Lamin C does not contain a CaaX motif, and terminates in an
alternative six amino-acid C-terminal end (VSGSRR) (Figure 4).
LMNA produces the major lamin A and C proteins (Figure 4), and the minor A∆10 and C2
proteins by alternative splicing within exon 10, and they are differentially expressed in a de‐
velopmentally and tissue specific way [13,15]. Lamin A∆10 is identical to lamin A, except
exon 10 is absent [16], and lamin C2 (which is expressed exclusively in germ cells) is identi‐
cal to lamin C, except an alternative exon, 1C2, located in intron 1 of LMNA, codes for the N-
terminal head domain [17,18]. A TATA-like promotor sequence (TATTA) for RNA
polymerase attachment, and a CAT-box for RNA transcription factor attachment, lie 236 and
297 base pairs upstream of the ATG initiation codon [6,13].
A-type lamins are expressed only in differentiated cells, suggesting that they have a role in
stabilising differential gene expression [15,16,19,20]. The main products in somatic cells are
lamins A and C, with C2 and AΔ10 being less common isoforms, lamin C2 being specific to
the testes [6,13,16,21]. The first 566 amino acids of lamins A and C are identical. However, at
the C-terminals lamin A has 98 unique amino acids, and as with lamin B1 and B2, ends in a
CaaX box motif, whilst lamin C has 6 unique terminal amino acids.
The second family of lamins, the B-type lamins, consist of lamin B1 encoded by the LMNB1
gene, and lamin B2 and B3, encoded by the LMNB2 gene. At least one of these B-type lamins
are expressed in all cell types [13,22-25]. Lamin B3 is a minor variant, arising from differen‐
tial splicing and alternative polyadenylation of LMNB2 and is expressed in male germ cells
[24]. B-type lamins have a CAAX motif and are constitutively farnesylated, whereas lamin A
loses its farnesyl group once targeted to the lamina [26].
The maturation process for lamin A, lamin B1 and B2 is detailed below, with these post-
translational modifications taking place in the nucleus [27].
• Prenylation: A farnesyl or geranylgeranyl isoprenoid group is covalently attached to the
cysteine of the CaaX motif of prelamin A, lamin B1 and B2 by farnesyltransferase or gera‐
nylgeranyltransferase-I, respectively.
• Cleavage: The terminal -aaX amino acids are removed by RCE1 and FACE1 for prelamin
A, and by RCE1 alone for lamin B1 and B2.
• Methylation: The now exposed C-terminal farnesylcysteine undergoes a methylation step,
performed by a carboxymethyltransferase, isoprenylcysteine carboxyl methyltransferase
(ICMT) [28]. This is the final post-translational step for B-type lamins, therefore they re‐
tain the farnesylcysteine α-methyl ester at the C-terminus.
• Second cleavage (for prelamin A only): FACE1 cleaves the carboxy-terminal 15 amino




cation step completes the post-translational modification of prelamin A to mature lamin
A. This maturation is thought to aid localisation of lamin A to the nuclear rim [30,31].
2. Laminopathies
Diseases caused by mutations in the LMNA gene are collectively known as primary lamino‐
pathies [32], whereas mutations in genes coding for B-type lamins (LMNB1 and LMNB2),
prelamin A processing proteins (such as ZMPSTE24), or lamin-binding proteins (such as
EMD, TMPO, LBR and LEMD3) are known as secondary laminopathies [33,34]. At present,
458 different mutations from 2,206 individuals have been identified in the LMNA gene
(www.umd.be/LMNA/). These mutations can be de novo or heritable, with a gain- or loss-of-
function effect, and with severity ranging from minor arrhythmia arising in adolescence to a
neonatally lethal tight skin condition [35]. Unlike with the LMNA gene, there are only a few
mutations found affecting B-type lamins [36]. This is most likely due to the wide-ranging
and non-redundant functions of lamin B1 in early growth and development [29].
Laminopathies are caused by a heterogeneous set of pleiotropic mutations affecting univer‐
sally expressed genes. However, their effects can be tissue specific to a degree, allowing for
categorisation into five groups (Table 1). Striated muscles are affected in muscular dystro‐
phies, peripheral nerves are affected in neuropathies, adipose tissue in lipodystophies, sev‐
eral tissues affected with premature development of multiple markers of senescence in
segmental progeriod diseases, and finally diseases displaying symptoms from more than
one category are known as overlapping syndromes.
2.1. Muscular dystrophies
Within this following section, selected muscular dystrophies will be detailed, while Table 2
shows a complete listing of known muscular dystrophy laminopathies, at the time of writing.
2.1.1. Emery-dreifuss muscular dystrophy
Emery-Dreifuss muscular dystrophy (EDMD), first described in 1955 [37], is the most preva‐
lent laminopathy, affecting 1 in 100,000 births. It is also a prototypical laminopathy, occur‐
ring both as a primary and secondary laminopathy. The most commonly occurring form is
autosomal dominant (AD-EDMD). It also occurs as an autosomal recessive (AR-EDMD) or
X-linked (XL-EDMD) form [38,39]. Mutations in the emerin gene are responsible for XL-
EDMD [40-43], while mutations in the LMNA gene have been found to cause AD-EDMD,
AR-EDMD and sporadic EDMD [44-47]. It most commonly occurs with nonsense mutations,
although there has also been a report of at least one case with a premature stop codon in
exon 1 of LMNA resulting in loss-of-function and haploinsufficiency as the genetic mecha‐
nism (Figure 4). The similarities in the clinical features of EDMD irrespective of whether the
causative mutation is affecting emerin or lamin A/C indicates a close functional relationship
between these proteins. Emerin mediates linkage between membranes and the cytoskeleton,
and is closely linked to lamins [40].
Genetic Disorders30
Laminopathy Acronym OMIM Locus Gene
Muscular dystrophy
Cardiomyopathy, dilated, 1A CMD1A 115200 1q22 LMNA
Emery-Dreifuss muscular dystrophy 1, X-linked EDMD1 310300 Xq28 EMD
Emery-Dreifuss muscular dystrophy 2, AD EDMD2 181350 1q22 LMNA
Emery-Dreifuss muscular dystrophy 3, AR EDMD2 181350 1q22 LMNA
Emery-Dreifuss muscular dystrophy 4, AD EDMD4 612998 6q25.1-q25.2 SYNE1
Emery-Dreifuss muscular dystrophy 5, AD EDMD5 612999 14q23.2 SYNE2
Emery-Dreifuss muscular dystrophy 6, X-linked EDMD6 300696 Xq26.3 FHL1
Heart-hand syndrome, Slovenian type HHS-S 610140 1q22 LMNA
Malouf syndrome MLF 212112 1q22 LMNA
Muscular dystrophy, congenital MDC 613205 1q22 LMNA
Muscular dystrophy, limb-girdle, type 1B LGMD1B 159001 1q22 LMNA
Lipodystrophy
Acquired partial lipodystrophy APLD 608709 19p13.3 LMNB2
Lipodystrophy, familial partial, 2 FPLD2 151660 1q22 LMNA
Mandibuloacral dysplasia with type A lipodystrophy MADA 248370 1q22 LMNA
Mandibuloacral dysplasia with type B lipodystrophy MADB 608612 1p34.2 ZMPSTE24
Neuropathies
Adult-onset autosomal dominant leukodystrophy ADLD 169500 5q23.2 LMNB1
Charcot-Marie-Tooth disease, type 2B1 CMT2B1 605588 1q22 LMNA
Segmental progeroid diseases
Hutchinson-Gilford progeria syndrome HGPS 176670 1q22 LMNA
Restrictive dermopathy RD 275210 1p34.2/1q22 ZMPSTE24/LMNA
Atypical Werner syndrome AWRN 277700 8p12 RECQL2
Overlapping syndromes
Hydrops-Ectopic calcification-moth-eaten skeletal
dysplasia HEM 215140 1q42.12 LBR
Pelger-Huet anomaly PHA 169400 1q42.12 LBR
Reynolds syndrome RS 613471 1q42.12 LBR
Buschke-Ollendorff syndrome BOS 166700 12q14.3 LEMD3
Melorheostosis with osteopoikilosis MEL 155950 12q14.3 LEMD3
Table 1. A summary of primary and secondary laminopathies, grouped into five categories. LMNA, Lamin A/C;
EMD, Emerin; SYNE1, Nesprin-1; SYNE2, Nesprin-2; FHL1, four and a half LIM domains; LMNB1, lamin B1; LMNB2,
lamin B2; ZMPSTE24, zinc metallopeptidase (STE24 homolog); RECQL2, Werner syndrome, RecQ helicase-like; LBR,




Figure 2. Lower limb imaging of skeletal muscles from patients with laminopathies. Leg muscles from an unaf‐
fected control individual (A), a 44 years old female with LGMD1B, LMNA c.673C>T, p.R225X (B), and a 50 years old
male with EDMD2, LMNA c.799T>C, p.Y267H (C). While the LGMD1B muscle shows a mild involvement of the medial
head of gastrocnemius and moderate involvement of soleus (B) there is a moderate to severe involvement of the same
muscles in the EDMD2 patient (C). Photo courtesy of Dr. Nicola Carboni and Dr. Marco Mura, University of Cagliari,
Sardinia, Italy.
EDMD is characterised by an onset in the teenage years of a slow, progressive wasting of
skeletal muscle tissue in the shoulder girdle and distal leg muscles. This atrophy leads to
muscle weakness around the humerus and fibula (a pattern described as scapulo-humero-
peroneal), early contractures of the pes cavus (resulting in high arched feet), proximal mus‐
cles of the lower leg and upper arm, and the elbow and Achilles tendons. Muscle cell
damage is indicated by elevated serum creatine kinase levels. Muscle pathology shows var‐
iations in muscle fibre sizes and type-1 fibre atrophy. Cardiac muscle is also affected, with
problems arising in early adulthood. Atrial rhythm disturbances, atrioventricular conduc‐
tion defects, arrhythmias and dilated cardiomyopathy with atrial ventricular block lead to
severe ventricular dysrhythmias and death [38,48].
2.1.2. Limb-girdle muscular dystrophy, type 1B
Limb-girdle muscular dystrophy, type 1B (LGMD1B) is a slowly progressive variant caused
by an autosomal dominant mutation of the LMNA gene, and is characterised by a limb-gir‐
dle pattern of muscular atrophy [49,50].
Patients display a classic limb-girdle pattern of muscle atrophy, with a proximal lower limb
muscular weakness starting by age 20. By the 30s and 40s upper limb muscles also gradual
weakened [49]. As in EDMD, serum creatine kinase levels were normal or elevated. The late
occurrence or absence of spinal, elbow and Achilles contractures distinguishes LGMD1B
from EDMD. Cardiac conduction abnormalities with dilated cardiomyopathy also occur.
One neonatally lethal case of LGMD1B was found to be caused by a homozygous LMNA
Y259X mutation [51].
2.1.3. Dilated cardiomyopathy with conduction defect 1
Dilated cardiomyopathy with conduction defect 1 (CMD1A) is a highly heterogeneous dis‐
ease, both genetically and phenotypically, with 16 genes currently found to be causatively
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mutated in cases of CMD1A [52]. Five heterozygotic missense mutations in the LMNA gene
were identified in 5 of 11 families with autosomal dominant CMD [53].
Dilated  cardiomyopathy  is  a  serious  cardiac  condition,  in  which  the  heart  becomes
weakened and enlarged,  with  downstream effects  on the  lungs,  liver  and other  organs.
Conduction  problems  and  dilated  cardiomyopathy  arise,  leading  to  frequent  heart  fail‐
ure  and  sudden  death  events.  Affected  family  members  have  little  or  no  associated
skeletal  myopathy.
2.1.4. Malouf syndrome
Malouf syndrome (MLF) is an extremely rare disorder with only a handful of cases descri‐
bed in the literature. The disease has been found to be caused by one of two mutations in
exon 1 of the LMNA gene. These mutations, A57P and L59R (Figure 4), have been designat‐
ed as causing AWS or atypical HGPS, however genital anomalies and missing progeroid
features suggest instead a distinct laminopathy [54,55].
In males primary testicular failure, and in females premature ovarian failure, is a character‐
istic feature of the disease. Mild to moderate dilated cardiomyopathy also occurs. Microgna‐
thia and sloping shoulders can give an atypical progeroid phenotype, however in patients
suffering from MLF there is no severe growth failure, alopecia, or atherosclerosis [54].
2.1.5. Heart-hand syndrome, Slovenian type
The heterogeneous family of genetic diseases characterised by both congenital cardiac dis‐
ease with limb deformities are known as Heart–hand syndromes (HHS). The Heart-hand
syndrome, Slovenian type (HHS-S) disorder has been shown to be caused by a mutation
(IVS9-12T-G) in intron 9 of the LMNA gene. It is an exceedingly rare disorder affecting sev‐
eral generations of a single family in Slovenia [56].
The characteristic changes to the hands and feet include short distal, and proximal phalang‐
es, as well as webbing or fusion of the fingers or toes. Dilated cardiomyopathy, with an
adult-onset progressive conduction disorder is also present, with sudden death due to ven‐
tricular tachyarrhythmia [56,57].
2.2. Lipodystrophies
Within this section, selected lipodystrophies were detailed, while Table 2 shows a complete
listing of known lipodystrophy laminopathies, at the time of writing.
2.2.1. Familial partial lipodystrophy type 2
Familial partial lipodystrophy type 2 (FPLD2; Dunnigan variety of familial partial lipodys‐
trophy) is an autosomal dominant lipodystophy, caused by a heterozygotic mutation in the
LMNA gene [58-60]. Mutations are clustered in exons 8 and 11, in the globular C-terminal
domain region of type-A lamins, the most common of which is a substitution of arginine at




FPLD2 shows the characteristic lypodystrophy reduction or loss of subcutaneous adipose
tissue in certain regions, starting in childhood, puberty or early adulthood. Patients gradual‐
ly lose fat from the upper and lower limbs, buttocks and trunk. However intramuscular and
bone-marrow fat are preserved. Adipose tissue may increase around the face, neck, back
and intra-abdominally [62]. Insulin resistance can occur with consequent complications of
diabetes, dyslipidaemia, hypertension and hepatic steatosis. Clinical features may also in‐
clude abnormalities of the menstrual cycle, hirsutism, and acanthosis nigricans.
2.2.2. Mandibuloacral dysplasia, type A and B
Mandibuloacral dysplasia (MAD) is an autosomal recessive disease, with strongly heteroge‐
neous clinical features. It is categorised into type A (MADA), which is caused by mutations
in the LMNA gene and type B (MADB), which is caused by mutations in the ZMPSTE24
gene [63-65].
Patients with MADA exhibit an acral loss of adipose tissue and a normal or increased fatty
layer in the face, neck and trunk, whereas MADB is marked by a severe progressive glomer‐
ulopathy, and generalised lipodystrophy affecting the extremeties, but also the face. Growth
retardation, osteolysis of the digits, pigmentary changes, mandibular hypoplasia and skele‐
tal anomalies occur in both variants. Patients may also display some symptoms of progeria,
and metabolic disorders such as insulin-resistant diabetes [63,66].
2.3. Neuropathies
2.3.1. Adult-onset autosomal dominant leukodystrophy
Adult-onset autosomal dominant leukodystrophy (ADLD) is an adult-onset neuropathy,
caused by a heterozygous tandem genomic duplication resulting in a duplication of the lam‐
in B1 gene, and a corresponding over-expression of lamin B1 [67,68].
ADLD is slowly progressive, with symptoms becoming apparent in the 40s and 50s, and are
markedly similar to progressive multiple sclerosis. These symptoms include symmetric de‐
myelination of the brain and spinal cord, autonomic abnormalities, as well as pyramidal and
cerebellar dysfunction. Pathological examination reveals that ADLD differs from progres‐
sive multiple sclerosis with a lack of astrogliosis and a preservation of oligodendroglia in
the presence of subtotal demyelination [67].
2.3.2. Charcot-Marie-Tooth disorder
Charcot-Marie-Tooth disorder (CMT) disorder was described simultaneously by Charcot,
Marie and Tooth in 1886. Today the disease is considered a spectrum of phenotypically and
genetically heterogeneous inherited neuropathies, with over 40 genes known to be associat‐
ed with the disorder (www.molgen.ua.ac.be/CMTMutations). The autosomal recessive var‐
iant, CMT2B1 (AR-CMT2A or CMT4C1) (OMIM: 605588), is known to be caused by a
mutation in LMNA [69,70]. All CMT disorders affect approximately 1 in 2,500 people, mak‐
ing them the most common group of inherited neuropathies [71,72]. Individuals with nor‐
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mal or slightly reduced sensory nerve conduction velocities (greater than 38 m/s) are
categorised as type 2 (CMT2), and are diagnosed as axonal neuropathies [73]. The disease-
causing mutation for CMT2B1 was identified as a homozygous LMNA c.829C>T mutation in
exon 5 of the LMNA gene, causing an R298C amino acid substitution [69,70].
Sufferers  of  CMT2B1  display  an  early  onset  muscle  wasting  in  the  distal  lower  limbs
(peroneal  muscular  atrophy  syndrome),  high  arched  feet  (pes  cavus),  with  a  curled,
claw-like  appearance  of  the  toes,  as  well  as  walking  difficulties  stemming  from  re‐
duced tendon reflexes [74,75].
2.4. Segmental progeroid diseases
2.4.1. Hutchinson-Gilford progeria syndrome
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare, fatal genetic disorder
that displays a marked phenotype of premature senility (see chapter on Hutchinson-Gilford
progeria syndrome). At least 90% of all HGPS cases are caused by a de novo mutation, where
a single base nucleotide in exon 11 of the LMNA gene is substituted (c.1824C>T, p.G608G).
This mutation results in an increased activation of a cryptic splice site in exon 11, which in
turn increases the production and subsequent accumulation of a truncated, partially proc‐
essed prelamin A protein that remains farnesylated, called progerin [76].
Individuals with HGPS are born normally but they present failure to thrive and scleroderm‐
atous skin with loss of subcutaneous fat usually before one year of age. The early symptoms
of HGPS also include short stature, and low body weight, which is followed by the occur‐
rence of a tight skin over the abdomen and thighs beginning at the age one or two. Alopecia,
scleroderma and the loss of subcutaneous fat also occur at early stages of the disease, suc‐
ceeded by thin epidermis, fibrosis in the dermis and a loss of skin appendages. Patients of‐
ten show micrognathia, prominent eyes and veins along with a small beaked nose.
Atherosclerosis and calcification of the thoracic aorta is recurrent and death occurs in the
early teenage years, most commonly due to cardiovascular complications [76-80].
2.4.2. Restrictive dermopathy
Restrictive dermopathy (RD) is a rare lethal autosomal recessive disease most often caused
by loss of function mutations of the ZMPSTE24 gene, and one case has been described with
a dominant mutation in intron 11 of the LMNA gene (Figure 4). Similar to HGPS, progerin
accumulation occurs, however at a greater level, and this accumulation has been proposed
to correspond to the severity of the clinical symptoms [81].
Intrauterine growth retardation is an early sign of RD, along with decreased foetal move‐
ment. Thin, translucent, tight skin, as well as joint contractures, respiratory insufficiency, a
small pinched nose, micrognathia and mouth in a characteristic fixed ‘o’ shape are the signs
of the disease at birth. Usually respiratory failure due to the tight skin leads to a neonatal




2.4.3. Atypical Werner syndrome
First described in 1904 by Otto Werner, Werner syndrome (WS) is caused by mutations in
the WRN gene, encoding a nuclear helicase [83]. However approximately 20% of patients di‐
agnosed with WS do not carry mutations in the WRN gene, and are classed as suffering
from atypical Werner syndrome (AWS). A minority of these have been found to carry heter‐
ozygous mutations in the LMNA gene, typically at the N-terminal region [84].
WRN is known as ‘progeria of the adult’ and symptoms, such as pubertal growth failure,
begin to emerge in the early teenage years. Then in the late teenage years or early 20s, skin
atrophy and ulcers, cataracts, type 2 diabetes mellitus, osteoporosis, atherosclerosis, hair
greying and alopecia follow. Lipoatrophy and a mild axonal sensorimotor polyneuropathy
can also occur. There is also an increased risk of malignancies, reduced fertility and gonadal
atrophy. Severe coronary, and peripheral artery disease is also present, and the most com‐
mon causes of death are myocardial infarction and cancer by a median age of 54 [85,86].
2.5. Overlapping syndromes
2.5.1. Hydrops-Ectopic calcification-moth-eaten skeletal dysplasia
Hydrops-Ectopic calcification-moth-eaten (HEM) skeletal dysplasia is an extremely rare, au‐
tosomal recessive lethal chondrodystrophy, which was first described by Greenberg in 1988,
in an examination of two sibling foetuses. A 7-bp, homozygous 1599–1605 TCTTCTArCTA‐
GAAG substitution in exon 13 of the lamin B receptor gene (LBR), gave rise to a premature
stop codon, resulting in a truncated protein and loss of LBR activity [87,88].
In  utero  radiological  examination  revealed  ectopic  calcifications,  a  ‘moth  eaten’  appear‐
ance  of  the  shortened  tubular  bones.  Extramedullary  erythropoiesis  was  also  found  in
both foetuses [89].
2.5.2. Pelger-Huet anomaly
Pelger-Huet anomaly (PHA) is a benign, autosomal dominant blood disorder, with charac‐
teristic misshapen, hypolobulated nuclei and abnormally course chromatin in blood granu‐
locytes, caused by a mutation in the LBR gene [89,90]. As PHA was found in relatives to two
HEM cases, it is thought that these disorders may be related [91].
Heterozygous patients are clinically normal, while homozygosity has been associated with
skeletal dysplasia and early lethality in animal models, although at least one case of non-
lethal homozygotic PHA has been found in humans [92].
2.5.3. Reynolds syndrome
Reynolds syndrome (RP) is caused by a heterozygous mutation in the LBR gene, and was
first described in 1971 by Reynolds et al. [93].
RP displays a highly heterogeneous set of clinical features similar to the elements of CREST
syndrome (CREST is an acronym that stands for calcinosis, Raynaud's phenomenon, esoph‐
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ageal dysmotility, sclerodactyly, and telangiectasia). These symptoms include scleroderma,
liver disease, telangiectasia, eosophageal varicies and Raynaud’s phenomenon [94].
2.5.4. Osteopoikilosis/Buschke-Ollendorff syndrome
Osteopoikilosis/Buschke-Ollendorff syndrome (BOS) is a highly penetrant, benign, rare, au‐
tosomal dominant bone disorder. It is caused by a mutation in the LEMD3 gene, which enc‐
odes the MAN1 protein, an integral protein of the inner nuclear membrane. BOS gives rise
to osteopoikilosis with subcutaneous nevi or nodules [95], and is known as osteopoikilosis if
no skin phenotype is present [96]. It displays an extremely variable set of clinical features
even within the same family [97].
The  osteopoikilosis  is  revealed  by  radiographs  as  numerous  and  widespread  grain-  to
pea-sized areas  of  increased bone density,  most  often in  the  cancellous bone regions of
the  epiphyses  and  metaphyses,  although  they  are  found  in  almost  all  bones  in  the
body,  with the exception of  the  cranium where they are  rarely  found.  The skin pheno‐
type is  manifested as firm lesions,  which histologically are revealed to be either elastic-
type  (juvenile  elastoma)  or  collagen-type  (dermatofibrosis  lenticularis  disseminata)  nevi.
Joint  stiffness  may also be present  [98].
2.5.5. Melorheostosis with osteopoikilosis
Melorheostosis  with  osteopoikilosis  (MEL)  has  been  thought  to  be  caused  by  a  muta‐
tion  in  the  LEMD3  gene  [96].  It  is  sometimes  a  features  of  BOS,  however  not  univer‐
sally,  and  evidence  for  LEMD3  mutations  causing  isolated  sporadic  melorheostosis  has
not  yet  been found [97].
MEL is characterised by the flowing hyperostosis of the tubular bone cortices, and some‐
times accompanied by abnormalities in surrounding soft-tissue, such as muscle atrophy,
joint-contractures, epidermal lesions or hemangiomas [96].
3. Linking genotype and phenotype of laminopathies
A marked change in heterochromatin is one of the most apparent features noted when ex‐
amining cells affected by laminopathies, from loci of diminished or clumped heterochroma‐
tin to total loss of peripheral heterochromatin [99-103]. This alteration of normal
heterochromatin, coupled with the known interactions between lamins and gene regulatory
proteins, defines a major constituent for the molecular mechanism behind laminopathies
[104]. Lamins have been shown to interact with proteins of the inner nuclear membrane
(emerin, myne-1, nesprin, LAP1 and LAP2, LBR and MAN1), and chromatin-associated pro‐
teins (H2a, H2B, H3-H4, Ha95, HP1 and BAF) [105-109]. These associations allow for gene
silencing by means of heterochromatin reorganisation, which could be a causative factor for
phenotypic changes [107]. Recruiting genes selectively to the inner nuclear membrane has




regulatory role of lamins is thought to underlie the tissue-specific symptoms observed in
laminopathies [34,110]. Tissue specific regulation of lamin A expression may also be an ex‐
planatory factor for tissue-specific symptoms. Low-level of prelamin A expression in the
brain has been shown to be due to a brain-specific microRNA, miRNA-9 [111], and miR-9
overexpression has been shown to alleviate nuclear blebbing in non-neural cells [112].
A mouse model with the LMNA H222P mutation for EDMD, displaying muscular dystro‐
phy and cardiomyopathy, was investigated in order to see how gene regulation and meta‐
bolic pathways are affected. This investigation revealed that the extracellular signal-
regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) branches of the Mitogen-
Activated Protein Kinase (MAPK) pathway were activated before any histological changes
were visible in the animals. This result was then in vitro confirmed by expressing the mutant
lamin A in vitro [113]. This MAPK signalling change is known to be associated with cardio‐
myopathy [114-116]. Similar results have been demonstrated in an EMD-knockout mouse
model for X-linked EDMD, in which MAPK pathway was activated [117].
The possibility of complex interactions between these different causative mechanisms, the
complex multirole functionality of lamins, along with widely varying environmental and
genetic co-factors affecting this spectrum of processes, would afford a possible explanation
for the heterogeneity of disease effects amongst the sufferers of laminopathies [48,118,119].
This variance of disease is one of the most fascinating aspects of laminopathies, the disparity
between how a very large family of mutations affecting many genes give rise to diseases
with such interrelated clinical features, and on the other hand how even amongst members
of a single family carrying the same mutation, disease manifestations are diverse and varia‐
ble. In AD-EDMD, heterozygous mutations in the LMNA gene can give rise to diverse ef‐
fects, varying from typical EDMD to no disease phenotype, while members of the same
family displaying the same mutation can be disease free, or suffer from contractures and
muscular atrophy [120].
The diversity of disease phenotypes in consanguineous patients with identical mutations,
such as disease onset, severity and progress, indicates that laminopathies are strongly influ‐
enced by disease modifiers such as genetic or environmental factors. For example, female
sufferers of FPLD2 exhibit a more pronounced phenotype than male [121], family members
with BOS can have both or just one of the bone and skin manifestations of that disease. Dif‐
ferent missense mutations at the same locus can also give rise to different laminopathies. For
example, in the LMNA gene, R527H and R527C result in MAD [122,123], while R527P causes
EMDM (Figure 4) [46]. The same missense mutation at the same locus can also give rise to
different laminopathies. For example, S573L in exon 11 of the LMNA in one family gave rise
to CDM1A, and in another FPLD2. Of five patients with the same E358K mutation in the
LMNA gene, three were diagnosed with autosomal dominant EDMD, one with early-onset
LGMD1B, and the last patient with congenital muscular dystrophy (Figure 4] [124]. Al‐
though the R644C mutation in exon 11 of LMNA is associated with CDM1A, three cases
with this mutation, and one with an R644H mutation were found to have very high variance
in their disease phenotypes, with features ranging from reduced foetal movement and a se‐
vere congenital muscular dystrophy-like phenotype, to mild skeletal muscle aberrations and
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severe and fatal hypertrophic cardiomyopathy [125, 126]. Even amongst members of the
same family with the same single nucleotide deletion at position 959, in exon 6 of LMNA,
one was classified as having DCM, one with EDMD and two with LGMD (Figure 4) [118].
This variation in phenotypes is a recurrent theme in the history of laminopathies, with mul‐
tiple examples in the literature, which reinforces the importance of disease modifiers.
Figure 3. Nuclei showing characteristic blebbing and herniation as a result of a mutation in the LMNA gene. (A) is
from sample AG06298 (unaffected HGPS parent) and (B) is from sample AG06917 (HGPS), and has the c.1824C>T, G608G
mutation in the LMNA gene. Approximately 50% of the AG06917 cells display blebs. Both are primary fibroblasts hybri‐
dised with an antibody for lamin A/C (green) and mitochondria (blue). Photo courtesy of Dr. Peter Berglund.
The LMNA missense mutations causing FPLD have been shown to result in nuclei with ab‐
normal shapes, herniated NE and increased fragility, and other laminopathies (including
HGPS, Figure 3) have also been found to cause severe changes in nuclear morphology
[76,127]. A-type lamin knockout cells display misshapen nuclei with herniations of the NE,
slight clustering of NPCs, with mislocalised emerin and B-type lamins. Whereas cells ex‐
pressing progerin display nuclear blebbing, thickening and honeycombing of the lamina, in‐
tranuclear lamina foci, loss of heterochromatin and NPC clustering [2,113,117,128-132]. In
PHA however, normally lobulated mature neutrophils exhibit hypolobulation and fail to
correctly function [90,133].
An altered nuclear integrity, leading to a weakness in cell structure and a susceptibility to
mechanical stress as a constituent of the causative mechanism for laminopathies is support‐
ed by the specificity of some laminopathies, such as HGPS or EDMD, to tissues affected by
high levels of mechanical stress (the skin, muscles and aortic arch), as well as the similarity
of muscular dystrophies caused by mutations in genes responsible for karyoskeleton, cytos‐
keleton and myotubule proteins to laminopathic muscular dystrophies. The unique expres‐




laminopathies. As no lamin B1 is expressed in muscle cells at all, when LMNA protein prod‐
ucts are expressed at reduced levels, or functionally impaired, lamin B2 alone must fulfil the
lamina requirements of the cell, undergirding the inner nuclear membrane, localising and
supporting key proteins of the inner nuclear membrane and organising and regulating the
heterochromatin [134].
Various hypotheses have been put forward to account for the muscle cell specificity of
EDMD [135]. Muscle cells contain very low or undetectable amounts of lamin B1, whereas in
most other cell types lamin B1 is a major lamin, leaving muscle cells more sensitive to loss of
function of either emerin or lamin A/C [42,136]. Emerin may also interact with transcription
factors or directly with DNA to cause specific gene regulation in muscle cells [137]. Finally,
muscle cells also undergo mechanical stress, and emerin, as part of a nucleo-cytoskeletal
system may have a protective role against mechanical stress [138].
Lamin A mutations have also been shown to cause premature exhaustion of somatic stem cell
populations, as well as stem cell dysfunction. As adult somatic stem cell population is depleted,
tissues undergoing a high rate of turnover, such as the skin, would be affected first [139,140].
Figure 4. Distribution of laminopathy-causing mutations causing mutations in the LMNA gene. Exons 1-9 and a
section of exon 10 encode Lamin C, Lamin A is a result of alternative splicing, adding exon 11 and 12, but removing
the lamin C specific part of exon 10 (lamin C specific amino acids marked in green). The conserved α-helical segments
of the central rod domain marked with coil 1a, coil 1b, and coil 2. Numbers refer to residues in the primary sequence.
Lipodystrophy causing mutations are clustered at exon 8, which codes for an Ig-like domain. The majority (80%) of
lipodystrophy cases are caused by a mutation at p.482. Similarly most (>90%) HGPS patients carry the de novo c.
1824C>T, G608G mutation, and most (85%) MAD patients carry a homozygous mutation at p.527 [76,141]. The size
of introns are not to scale. CDM1A, dilated cardiomyopathy, type 1A; EDMD, Emery–Dreifuss muscular dystrophy; MLF,
Malouf Syndrome; MDC, Muscular dystrophy, congenital; LGMD1B, limb girdle muscular dystrophy, type 1B; FPLD,
Dunnigan familial partial lipodystrophy; MAD, mandibuloacral dysplasia; CMT2B1, Charcot–Marie–Tooth disorder,
type 2B1; AWS, atypical Werner syndrome; HGPS, Hutchinson–Gilford progeria syndrome;
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A consistent  relationship  between  mutation  location  on  the  LMNA  gene  and  its  subse‐
quent  effect  is  difficult  to  pin  down,  as  shown  in  figure  4,  mutations  causing  muscu‐
lar  dystrophies  are  spread  all  along  the  gene.  However  the  majority  of  mutations
causing  lipodystrophies  are  located  at  codon  R482,  which  is  conserved  across  human,
mouse,  rat  and  chicken  lamin  A/C  genes  [7].  Additionally,  the  vast  majority  of  seg‐
mental  progeriod  cases  are  caused  by  mutations  at  G608,  which  affect  splicing  [34].
The  position  of  the  mutation  on  the  LMNA  gene  relative  to  the  NLS  seems  to  play  a
significant  role  in  the  type  of  laminopathy  induced.  When  laminopathies  were  segre‐
gated  on  the  basis  of  which  organs  they  showed  clinical  pathology  in,  it  was  found
that  there was a  strong correlation between the position of  the mutation relative to  the
NLS,  and the  group the  resultant  laminopathy was  sorted into.  For  example  laminopa‐
thies  with  mutations  upstream  (N-terminally)  of  the  NLS  were  more  likely  to  display
cardiomyopathy  and  muscle  atrophy,  while  laminopathies  with  mutations  downstream
of  the  NLS (C-Terminally)  were  more  likely  to  have progeriod symptoms [32].  The tis‐
sue-specificity  of  the  mutations  may  then  be  correlated  with  whether  the  mutation  af‐
fects  the  conserved  structurally  important  rod-domain  that  lies  upstream  of  the  NLS,
or  if  it  affects  the  region  downstream  of  the  NLS  which  has  been  shown  to  associate
with chromatin and/or transcription factors  (Figure 4)  [142].
It  was  suspected  that  a  duplication  of  the  LMNB1  gene  was  the  cause  behind  ADLD
as  LMNB1  was  the  only  gene  in  the  duplicated  region  expressed  in  the  brain,  as  well
as  detection  of  increased  levels  of  lamin  B1  in  the  brains  of  affected  individuals.  The
role  of  LMNB1  was  confirmed  by  over-expressing  lamin  B1  in  Drosophila  melanogaster,
and in HEK293 cells,  which showed a strong phenotype,  and nuclear folding and bleb‐
bing respectively [67,68].
Finally,  a  link  between  levels  of  progerin  produced  in  laminopathies  that  exhibit  an
accumulation of  the mutant  lamin A/C precursor,  and both the severity and age of  on‐
set  of  the  phenotype  has  been  shown.  RD is  considered to  be  similar  but  more  severe
than  HGPS,  with  a  correspondingly  higher  rate  of  prelamin  A  accumulation  [143,144].
Two  cases  of  a  Werner  syndrome-like  form  of  progeria  displayed  a  progeria-like  as‐
pect  with  middle  age  onset  coronary  artery  disease,  with  a  level  of  progerin  that  was
one quarter  of  that  seen in HGPS cells  [85].  Further  proof  of  the toxicity  of  accumulat‐
ed  progerin  is  shown  by  the  decrease  of  progerin  levels  in  cell  cultures  by  treatment
with  rapamycin,  with  a  resultant  rescue  of  the  phenotype  [145].  As  allele  dependant
differences  in  expression  of  the  LMNA  gene  have  been  observed,  with  one  allele  ac‐
counting  for  70%  and  the  other  accounting  for  30%  of  the  expressed  lamin  A  and  C
transcripts,  one  explanation  for  phenotype  variation  might  depend  on  which  allele  the
disease-causing mutation is  located [146].
These details paint a complex picture of a heterogeneous family of mutations resulting in
varying and overlapping phenotypes, with a diversity in severity and age of onset resulting






Mouse models have yielded invaluable knowledge about the functions of the LMNA gene and
about the molecular effects of mutations that cause laminopathies. Possibilities for treatment
have also been explored with mouse models for these diseases. Various methods have been
used to produce strains of mice with similar phenotype to those shown in human laminopa‐
thies. Most of the available relevant models have been summarized in the table below (Table 2).
Mice that were thought to completely lack A-type lamin expression were created in order to
study a model with no expressed lamin A/C. These Lmna-null mice are phenotypically nor‐
mal at birth, but develop a condition similar to EDMD. By two to three weeks of age they
display a growth retardation and arrest. Skeletal abnormalities including kyphosis occur,
and a loss of white adipose tissue was noted. Cardiac myopathies also develop, and death
occurred within eight weeks. An analysis of mouse embryonic fibroblasts (MEFs) showed
misshapen, herniated nuclei. Mice heterozygous for Lmna were phenotypically normal [101].
The phenotype for Lmna knockout mice showed neuropathic features, decreased axon densi‐
ty paired with increased axon diameter and non-myelinated axons, features that are mark‐
edly similar to human axonopathies [70,101]. The only known case of an LMNA-null human,
with homozygous nonsense mutations in LMNA, resulted in a perinatal lethality, exhibiting
small size, retrognathia, severe limb and phalangeal contractures, fractures in the femur and
arm, muscular dystrophy. Death was due to respiratory failure [51]. Apart from these differ‐
ences in disease severity, changes in the proliferation of LMNA-null fibroblasts were also
markedly dissimilar for human as compared to mouse. Patient fibroblasts showed a reduced
proliferation [160], while MEFs showed an increased proliferative potential compared to
wild-type MEFs [161]. Recently these mice have been found to express a C-terminally trun‐
cated Lmna gene product, missing residues 461–657 of wild-type lamin A, which are normal‐
ly encoded by exons 8–11. This expression, both on a transcriptional and protein level,
perhaps explains the difference in fibroblast proliferative potential between human LMNA-
null fibroblasts and MEFs from this mouse model, as well as raising questions about the
many studies that have been performed on these mice [162].
Mice with the Zmpste24 gene knocked out were created independently by two groups
[151,163]. While loss of the ZMPSTE24 gene due to homozygous or compound heterozygous
mutations in humans results in the neonatally lethal disease, RD, these mouse models did
not display an equivalent phenotype. The Zmpste24-/- mice lack the ability to convert farne‐
sylated prelamin A to mature lamin A, and so accumulate prelamin A at the nuclear rim,
resulting in aberrant nuclear morphology. Normal at birth, they develop a HGPS-like condi‐
tion, showing growth retardation, alopecia, kyphosis, weight loss and incisor defects. Spon‐
taneous bone fractures also occur as the animals age and death occurs prematurely, at 20-30
weeks [150,151]. That the accumulation of prelamin A was the direct cause of the disease
state was demonstrated when Zmpste24-/- mice with only one allele for the Lmna gene were
compared to Zmpste24-/- mice with two copies of Lmna. The Zmpste24-/-Lmna +/- mice had sig‐
nificantly reduced levels of prelamin A compared to Zmpste24-/-Lmna +/+ mice. All disease
phenotype was missing, and the ratio of misshapen nuclei to normal was also reduced [103].
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Mouse model Description Pathology Reference
Lmna −/− These Lmna null mice were designed to
produce no lamin A or C. Recently however
they have been found to produce a
truncated lamin A protein.
Postnatal lethality, with cardiomyopathy and
muscular dystrophy
[101,147]
Lmna GT-/- These mice have a total loss of lamin A/C. Growth retardation, developmental heart defects,
skeletal muscle hypotrophy, decreased
subcutaneous adipose tissue. Death occurs at 2 to 3
weeks post partum, without dilated
cardiomyopathy or an obvious progeroid
phenotype.
[148]
Lmna LCO/LCO These lamin C only mice carry a mutant
Lmna allele that yields lamin C exclusively,
without lamin A.
No disease phenotypes and a normal lifespan. [132]
Lmna LAO/LAO Mature lamin A only mouse, bypassing
prelamin A synthesis and processing.
No detectable pathology, fibroblasts show
misshapen nuclei.
[149]
Zmpste24 −/− These mice are null for the endoprotease
responsible for the final cleavage step in
prelamin A maturation, leading to an
accumulation of farnesylated pre-lamin A.
Mice have rib fractures, osteoporosis, muscle
weakness and die at 6–7 months.
[150]
[99]
Postnatal growth retardation, shortened lifespan,
loss of fat layer and muscular dystrophy.
[151]
Lmna N195K/N195K These mice have a missense CDM1A-
associated lamin A mutation, N195K.
Postnatal death associated with cardiomyopathy.
MEFs showed nuclear abnormalities.
[152]
Lmna H222P/H222P These mice have a missense EDMD-
associated lamin A mutation, H222P.
These mice show a stiff walking posture and cardiac
dysfunction. Death occurs by 9 months of age. MEFs
showed nuclear abnormalities.
[153]
Lmna HG/HG These mice carry an Lmna-knock in allele
that produces progerin. Mice accumulate
farnesyl–prelamin A.
Heterozygous mice, Lmna HG/- , express large
amounts of progerin and develop many disease
phenotypes of progeria. MEFs display nuclear
blebbing.
[154]
LmnaL530P/L530P These mice have a L530P mutation in the
lamin A gene that is associated with EDMD
in humans.
Homozygous mice display defects consistent with
HGPS, and die within 4-5 weeks of birth.
[155]
Lmna M371K cDNA with mis-sense mutation expressed
with a heart specific promoter.
Cardiomyopathy and early postnatal lethality [156]
Lmna G609G The wild-type mouse lmna gene is replaced
with a copy containing the c.
1827C>T;p.G609G mutation. This is the
equivalent of the HGPS c.1824C>T;p.G608G
mutation in the human LMNA gene.
Growth retardation, weight loss, cardiovascular
problems and shortened lifespan.
[157]
Lmnb1 −/− These mice have an insertional mutation in
Lmnb1, resulting in a mutant lamin B1
protein missing several functional domains.
Mice survive embryonic development, however die
at birth with lung and bone defects.
[29]
Emd −/− These mice do not express emerin. Mice overtly normal but with slightly retarded
muscle regeneration.
[158,159]




A mouse model for EDMD was created by knocking out the Emd gene. These animals had
no abnormal clinical features outside of a slightly retarded muscle regeneration, and altered
motor coordination when tested on a rotarod [158,159]. The human AD-EDMD mutations in
the LMNA gene, H222P (with a histidine substituting for a proline at residue 222) and
N195K (with a lysine substituting for asparagine at residue 195), have also been used to cre‐
ate mouse models for AD-EDMD. Again, mice heterozygous for the mutations are indistin‐
guishable from wild-type animals. Mice with two copies of the mutation however, showed a
muscular dystrophy and cardiomyopathy phenotype [152,153].
Knock-in mouse models such as the LmnaG609G mouse model closely mimic the human dis‐
ease HGPS. A copy of the wild-type mouse lmna gene was replaced with a copy containing
the c.1827C>T;p.G609G mutation, the equivalent of the HGPS c.1824C>T;p.G608G mutation
in the human LMNA gene. This gave a phenotype of growth retardation, weight loss, cardi‐
ovascular problems and curtailed lifespan, correlating neatly with the clinical features found
in the human disease. However, the disease symptoms were most marked and similar in the
homozygous state, whereas in humans an autosomal dominant state with only a single mu‐
tated allele confers the disease state [157].
A mouse model where only lamin-C is produced (LmnaLCO), without producing any prela‐
min A or mature lamin A. These LmnaLCO/LCO animals were entirely healthy, with only a min‐
imal alteration to normal nuclear shape [132]. More recently a mouse model where only
mature lamin A is expressed was made. These LmnaLAO/LAO mice synthesis mature lamin A
without any prelamin A synthesis or processing steps. They display no disease phenotype,
but do have an increased level of nuclear blebbing compared to wild-type, demonstrating
that bypassing prelamin A processing and directly synthesising mature lamin A has little ef‐
fect on the transportation of lamin A to the nuclear envelope [149].
In order  to  study early post-natal  development  effects  caused by loss  of  lamin A/C,  an
LmnaGT-/-  model  was  created.  This  model  simultaneously  inactivates  and reports  the  ex‐
pression of  Lmna.  Loss  of  lamin A/C resulted in growth retardation,  developmental  de‐
fects  of  the  heart,  skeletal  muscle  hypotrophy,  loss  of  subcutaneous  adipose  tissue  and
impaired  ex  vivo  adipogenic  differentiation.  Premature  death  occurred  at  two  to  three
week post partum [148].
A mouse model was created using a heart-selective promoter (α-myosin heavy chain pro‐
moter) to control the expression of human normal lamin A, and lamin A containing the
EDMD causing mutation M371K. Mice expressing the wild-type human lamin A were born
at slightly less than expected rates, and had a normal lifespan. However, mice expressing
mutant M371K lamin A exhibited a much higher risk of prenatal death, and were born at
only a fraction (0.07) of the expected frequency. Those animals that were born died within
2-7 weeks, and displayed pulmonary and cardia edema. Cardiac cells from these mice
showed abnormal, convoluted nuclear envelopes with clumped chromatin and intranuclear
foci of lamins [156].
Mouse models of laminopathies are limited by the gross physiological differences between
rodent (mouse models being the most relevant models used to investigate laminopathies)
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and human. However, despite the limitations of mouse models, the advantages are legion;
being able to study very rare diseases at any stage of disease, with limitless sampling, tem‐
poral and physically controlled expression of mutant protein, and with the possibilities for
testing different type of treatment.
5. Treatment
Current treatments for laminopathies are largely symptomatic,  controlling the secondary
effects  of  the  disease.  Corrective  surgery  is  used to  treat  the  EDMD contractures,  coro‐
nary artery bypass surgery for HGPS, pacemaker installation or heart transplantation for
DCMI or  LGMD1B patients  [164].  FPLD2 patients  with  diabetes  mellitus  and hyperten‐
sion are treated with antidiabetic drugs, angiotensin converting enzyme inhibitors,  calci‐
um channel blockers and beta blockers [52,165,166]. The administration of a recombinant
methionyl  human  leptin  has  been  tried  with  some  success  in  patients  suffering  from
FPLD, giving rise to improved fasting glucose concentrations, insulin sensitivity, and tri‐
glyceride  levels  [167,168].  The  impairment  of  pre-adipocyte  differentiation,  an  impair‐
ment which is brought about by the negative effects of prelamin A accumulation on the
rate  of  DNA-bound SREBP1,  may also  be  treated  with  troglitazone,  a  PPAR-gamma li‐
gand which promotes the adipogenic program [169].
Curative treatment for laminopathies that are autosomal-recessive involving loss-of-func‐
tion of a protein, such as EDMD-AR, would require the expression of a healthy wild-type
allele in the affected tissue. However, autosomal dominant laminopathies require a more
complex treatment, in which the production, modification and/or the effect of the mutant
protein also need to be eliminated. For example, in a phase II clinical trial with HGPS pa‐
tients, lonafarnib, a farnesyl transferase inhibitor (FTI) is being given as treatment (see chap‐
ter on Hutchinson-Gilford progeria syndrome) [170]. FTI is normally used as an anti-tumour
treatment, but it also reduces the amount of progerin produced by inhibiting the farnesyla‐
tion of prelamin A. Previous experiments with FTIs in cell cultures showed marked im‐
provements, with a reduction of misshapen nuclei [171]. With mouse models for HGPS an
improvement in disease phenotype was noted, although no total reversal was apparent
[172-176]. This may be due to the fact that although FTI treatment inhibits the farnesylation
of prelamin-A by farnesyl transferase, a secondary modification pathway, a geranylgerany‐
lation by geranylgeranyltransferase, allows prelamin A to be processed into progerin de‐
spite the FTI treatment [177]. However, a combination of statins (a potent HMG-CoA
reductase inhibitor, used to inhibit the production of cholesterol in the liver) and bisphosph‐
onates (a class of drugs used to treat osteoporosis), was used to inhibit the synthesis of far‐
nesyl pyrophosphate, a co-substrate of farnesyltransferase and a precursor of a substrate for
geranylgeranyltransferase I. This combination inhibits prenylation, and when used to treat
laminopathies, resulted in an increased longevity, reduced oxidative stress, cellular senes‐
cence and improved phenotype in mice [61,154,172,178,179]. A triple drug trial was initiated
in 2009 to examine the efficacy of treatment involving an FTI, a statin and a bisphosphonate,




Long-term treatment with FTIs is not without risks. All CaaX box/motif proteins would have
their farnesylation processing inhibited, which would mean an inhibition of lamin-B matura‐
tion. Non-farnesylated lamins might also accumulate in the cell, with unexpected effects. In a
mice  model  where  non-farnesylated  prelamin-A  was  solely  expressed,  with  the  CaaX
motif/box mutated to SAAX, a cardiomyopathy was observed to occur [180]. In HIV treatment,
acquired lipodystrophy is a possible side-effect of the use of HIV protease inhibitors, which
cause pre-lamin A accumulation [181]. This pre-lamin accumulation was also observed in fi‐
broblasts from FPLD2 patients, further hinting at the toxicity of pre-lamin A accumulation [61].
Rapamycin, an immunosuppressant antibiotic drug, has also been examined as a possible
treatment in laminopathies. Rapamycin treatment in HGPS cell cultures resulted in reduced
nuclear blebbing and decreased rates of senescence, as well as a marked reduction of progerin
and prelamin A levels, a restoration of wildtype LAP2α, BAF and trimethylated H3K9 organi‐
sation, and a rescue of the normal chromatin phenotype. These effects come about by means of
autophagic degradation of prelamin A, triggered by inactivation of the inhibitory mammalian
target of rapamycin (mTOR) dependent pathway [145,182]. In an Lmna−/− mouse model treat‐
ment with rapamycin was shown to improve cardiac and skeletal muscle function, as well as
improving the survival rate [183]. In the LmnaH222P/H222P mouse model, rapamycin treatment was
shown to improve cardiac function [184]. This mouse model has also been treated with other
inhibitors of MAPK/ERK kinase (MEK) (the mitogen-activated protein kinase (MAPK kinase)
that activates extracellular signal-regulated protein kinase (ERK)), in order to see if administra‐
tion would alleviate or prevent the cardiomyopathy. The MEK-inhibitor treated animals were
indistinguishable from wild-type animals, while untreated control animals displayed reduced
ejection fraction, indicating a dilated cardiomyopathy. Interestingly, abnormal elongation of
heart cell nuclei was noted in untreated control animals, but was not observed in the treatment
group [113,185]. As with FTIs, the long-term treatment of patients with rapamycin would en‐
tail the acceptance of know side-effects, such as lung toxicity, insulin resistance, cataracts and
testicular degeneration [186-189].
Pre-lamin A antisense oligonucleotides were used to reduce pre-lamin A levels, with a resul‐
tant decrease in misshapen nuclei. The most common HGPS point mutation causes an in‐
creased usage of a cryptic splice site in exon 11, CAG#GTGGGC, which is also used at near-
undetectable levels in wild-type cells. Antisense morpholino oligonucleotides directed to
this site resulted in an improvement of HGPS fibroblast disease phenotype [190]. RNA inter‐
ference has also been used to successfully improve proliferation and nuclear morphology, as
well as reducing senescence in fibroblasts expressing mutant lamin A [191]. In another ex‐
periment exon 11 splice donor site antisense oligonucleotides were also used to promote the
alternative splice pathway, leading to an increased in progerin production in fibroblast cells,
and short hairpin RNA (shRNA) were then used to diminish this production in fibroblasts,
leading to an improvement of phenotype [192]. Morpholinos have also been used to target
the cryptic splicing event in mouse. The use of antisense morpholinos to the exon 10 lamin
A splice donor site and the c.1827C>T;p.G609G mutation of the LMNA transcript was shown
to reduce progerin levels, partially restore a wild-type phenotype and extend lifespan of a
mouse model for HGPS [157].
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In  light  of  the  recent  Glybera  Gene  therapy  [193],  future  gene  therapies  for  the  treat‐
ment  of  the cardiomyopathy prevalent  in  muscular  dystrophies  may also be an area of
interest  [194-196].
6. Conclusion
During the last decade the number of diseases found to be caused by mutations in lamin or
lamin associated genes has increased significantly. These phenotypically diverse diseases
have been categorised both phenotypically and genetically, and today research is focused on
both deciphering the pathogenic mechanisms behind their pathophysiological processes, as
well as understanding how such diverse pathologies can arise from this related family of
mutations. During that time the appreciated role for lamins has changed from being regard‐
ed merely as a structural scaffold for the nucleus, to a key element in DNA replication and
transcription, chromatin organisation, cell replication and differentiation. Future research is
sure to continue at an ever-increasing pace, especially as the development and integration of
next generation sequencing technologies and technologies that allows for global analysis of
the genome and epigenome into both research and clinical settings. For researchers this level
of genomic interrogation brings about unprecedented access to new information about our
genome, which will be valuable for the creation of maps of genetic and possibly epigenetic
variation that influence disease.
The laminopathies described in this review are without a doubt, exceedingly rare. However
by researching these rare conditions, it is hoped that we can shed light on their all too com‐
mon clinical symptoms, such as cardiac disease, metabolic disorders such as insulin resist‐
ance, and even ageing itself.
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